MicroRNAs and the glomerulus

Experimental Cell Research

Volumn 318, Issue 9, 2012, Pages 993-1000

  Kato, Mitsuo ^a   Park, Jung Tak ^a   Natarajan, Rama ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Diabetic nephropathy; Fibrosis; Glomerulus; Hypertrophy; MicroRNAs; TGF

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 192; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

BIOGENESIS; DIABETIC NEPHROPATHY; ENDOTHELIUM CELL; GLOMERULUS; HUMAN; KIDNEY CELL; KIDNEY FIBROSIS; KIDNEY INJURY; MESANGIUM CELL; NONHUMAN; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; REVIEW;

EID: 84859851733     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.02.034     Document Type: Review

References (79)

1. Foley R.N., Parfrey P.S., Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 1998, 32:S112-S119.
2. Brosius F.C., Khoury C.C., Buller C.L., Chen S. Abnormalities in signaling pathways in diabetic nephropathy. Expert. Rev. Endocrinol. Metab. 2010, 5:51-64.
3. Ziyadeh F.N. The extracellular matrix in diabetic nephropathy. Am J Kidney Dis 1993, 22:736-744.
4. Kato M., Yuan H., Xu Z.G., Lanting L., Li S.L., Wang M., Hu M.C., Reddy M.A., Natarajan R. Role of the Akt/FoxO3a pathway in TGF-beta1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease. J. Am. Soc. Nephrol. 2006, 17:3325-3335.
5. Kato M., Putta S., Wang M., Yuan H., Lanting L., Nair I., Gunn A., Nakagawa Y., Shimano H., Todorov I., Rossi J.J., Natarajan R. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat. Cell Biol. 2009, 11:881-889.
6. Mahimainathan L., Das F., Venkatesan B., Choudhury G.G. Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN. Diabetes 2006, 55:2115-2125.
7. Sharma K., Ziyadeh F.N. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995, 44:1139-1146.
8. Kato M., Zhang J., Wang M., Lanting L., Yuan H., Rossi J.J., Natarajan R. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:3432-3437.
9. Yamamoto T., Nakamura T., Noble N.A., Ruoslahti E., Border W.A. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:1814-1818.
10. Ziyadeh F.N., Hoffman B.B., Han D.C., Iglesias-De La Cruz M.C., Hong S.W., Isono M., Chen S., McGowan T.A., Sharma K. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:8015-8020.
11. Decleves A.E., Sharma K. New pharmacological treatments for improving renal outcomes in diabetes. Nat. Rev. Nephrol. 2010, 6:371-380.
12. Zhdanova O., Srivastava S., Di L., Li Z., Tchelebi L., Dworkin S., Johnstone D.B., Zavadil J., Chong M.M., Littman D.R., Holzman L.B., Barisoni L., Skolnik E.Y. The inducible deletion of Drosha and microRNAs in mature podocytes results in a collapsing glomerulopathy. Kidney Int. 2011, 80:719-730.
13. Harvey S.J., Jarad G., Cunningham J., Goldberg S., Schermer B., Harfe B.D., McManus M.T., Benzing T., Miner J.H. Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. J. Am. Soc. Nephrol. 2008, 19:2150-2158.
14. Shi S., Yu L., Chiu C., Sun Y., Chen J., Khitrov G., Merkenschlager M., Holzman L.B., Zhang W., Mundel P., Bottinger E.P. Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J. Am. Soc. Nephrol. 2008, 19:2159-2169.
15. Ho J., Ng K.H., Rosen S., Dostal A., Gregory R.I., Kreidberg J.A. Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury. J. Am. Soc. Nephrol. 2008, 19:2069-2075.
16. Nagalakshmi V.K., Ren Q., Pugh M.M., Valerius M.T., McMahon A.P., Yu J. Dicer regulates the development of nephrogenic and ureteric compartments in the mammalian kidney. Kidney Int. 2011, 79:317-330.
17. Ho J., Pandey P., Schatton T., Sims-Lucas S., Khalid M., Frank M.H., Hartwig S., Kreidberg J.A. The pro-apoptotic protein Bim is a microRNA target in kidney progenitors. J. Am. Soc. Nephrol. 2011, 22:1053-1063.
18. Wessely O., Agrawal R., Tran U. MicroRNAs in kidney development: lessons from the frog. RNA Biol. 2010, 7:296-299.
19. Sun Y., Koo S., White N., Peralta E., Esau C., Dean N.M., Perera R.J. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res. 2004, 32:e188.
20. Tian Z., Greene A.S., Pietrusz J.L., Matus I.R., Liang M. MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Res. 2008, 18:404-411.
21. Kato M., Arce L., Natarajan R. MicroRNAs and their role in progressive kidney diseases. Clin. J. Am. Soc. Nephrol. 2009, 4:1255-1266.
22. Long J., Wang Y., Wang W., Chang B.H., Danesh F.R. MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J. Biol. Chem. 2011, 286:11837-11848.
23. Kato M., Arce L., Wang M., Putta S., Lanting L., Natarajan R. A microRNA circuit mediates transforming growth factor-beta1 autoregulation in renal glomerular mesangial cells. Kidney Int. 2011, 80:358-368.
24. Long J., Wang Y., Wang W., Chang B.H., Danesh F.R. Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. J. Biol. Chem. 2010, 285:23457-23465.
25. Wang Q., Wang Y., Minto A.W., Wang J., Shi Q., Li X., Quigg R.J. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J. 2008, 22:4126-4135.
26. Kato M., Wang L., Putta S., Wang M., Yuan H., Sun G., Lanting L., Todorov I., Rossi J.J., Natarajan R. Posttranscriptional upregulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-{beta}-induced collagen expression in kidney cells. J. Biol. Chem. 2010, 285:34004-34015.
27. Inui M., Martello G., Piccolo S. microRNA control of signal transduction. Nat. Rev. Mol. Cell Biol. 2010, 11:252-263.
28. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
29. Davis B.N., Hilyard A.C., Nguyen P.H., Lagna G., Hata A. Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. Mol. Cell 2010, 39:373-384.
30. Davis B.N., Hilyard A.C., Lagna G., Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008, 454:56-61.
31. Suzuki H.I., Yamagata K., Sugimoto K., Iwamoto T., Kato S., Miyazono K. Modulation of microRNA processing by p53. Nature 2009, 460:529-533.
32. Kim D.H., Saetrom P., Snove O., Rossi J.J. MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:16230-16235.
33. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., Peterson A., Noteboom J., O'Briant K.C., Allen A., Lin D.W., Urban N., Drescher C.W., Knudsen B.S., Stirewalt D.L., Gentleman R., Vessella R.L., Nelson P.S., Martin D.B., Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10513-10518.
34. Tijsen A.J., Creemers E.E., Moerland P.D., de Windt L.J., van der Wal A.C., Kok W.E., Pinto Y.M. MiR423-5p as a circulating biomarker for heart failure. Circ. Res. 2010, 106:1035-1039.
35. Wang G., Kwan B.C., Lai F.M., Chow K.M., Kam-Tao Li P., Szeto C.C. Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. Dis. Markers 2010, 28:79-86.
36. Wang G., Kwan B.C., Lai F.M., Choi P.C., Chow K.M., Li P.K., Szeto C.C. Intrarenal expression of miRNAs in patients with hypertensive nephrosclerosis. Am. J. Hypertens. 2010, 23:78-84.
37. Wang G., Kwan B.C., Lai F.M., Choi P.C., Chow K.M., Li P.K., Szeto C.C. Intrarenal expression of microRNAs in patients with IgA nephropathy. Lab. Invest. 2010, 90:98-103.
38. Dai Y., Sui W., Lan H., Yan Q., Huang H., Huang Y. Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol. Int. 2009, 29:749-754.
39. Wang X.X., Jiang T., Shen Y., Caldas Y., Miyazaki-Anzai S., Santamaria H., Urbanek C., Solis N., Scherzer P., Lewis L., Gonzalez F.J., Adorini L., Pruzanski M., Kopp J.B., Verlander J.W., Levi M. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes 2010, 59:2916-2927.
40. Chung A.C., Huang X.R., Meng X., Lan H.Y. miR-192 mediates TGF-{beta}/Smad3-driven renal fibrosis. J. Am. Soc. Nephrol. 2010, 21:1317-1325.
41. Sun L., Zhang D., Liu F., Xiang X., Ling G., Xiao L., Liu Y., Zhu X., Zhan M., Yang Y., Kondeti V.K., Kanwar Y.S. Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192. J. Pathol. 2011, 225:364-377.
42. Sekido R., Murai K., Funahashi J., Kamachi Y., Fujisawa-Sehara A., Nabeshima Y., Kondoh H. The delta-crystallin enhancer-binding protein delta EF1 is a repressor of E2-box-mediated gene activation. Mol. Cell. Biol. 1994, 14:5692-5700.
43. Verschueren K., Remacle J.E., Collart C., Kraft H., Baker B.S., Tylzanowski P., Nelles L., Wuytens G., Su M.T., Bodmer R., Smith J.C., Huylebroeck D. SIP1, a novel zinc finger/homeodomain repressor, interacts with Smad proteins and binds to 5'-CACCT sequences in candidate target genes. J. Biol. Chem. 1999, 274:20489-20498.
44. Ponticos M., Partridge T., Black C.M., Abraham D.J., Bou-Gharios G. Regulation of collagen type I in vascular smooth muscle cells by competition between Nkx2.5 and deltaEF1/ZEB1. Mol. Cell. Biol. 2004, 24:6151-6161.
45. Zarjou A., Yang S., Abraham E., Agarwal A., Liu G. Identification of a microRNA signature in renal fibrosis: Role of miR-21. Am. J. Physiol. Ren. Physiol. 2011, 301:F793-F801.
46. Dey N., Das F., Mariappan M.M., Mandal C.C., Ghosh-Choudhury N., Kasinath B.S., Choudhury G.G. MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes. J. Biol. Chem. 2011, 286:25586-25603.
47. Zhong X., Chung A.C., Chen H.Y., Meng X.M., Lan H.Y. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J. Am. Soc. Nephrol. 2011, 22:1668-1681.
48. Denby L., Ramdas V., McBride M.W., Wang J., Robinson H., McClure J., Crawford W., Lu R., Hillyard D.Z., Khanin R., Agami R., Dominiczak A.F., Sharpe C.C., Baker A.H. miR-21 and miR-214 are consistently modulated during renal injury in rodent models. Am. J. Pathol. 2011, 179:661-672.
49. Zhang Z., Peng H., Chen J., Chen X., Han F., Xu X., He X., Yan N. MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Lett. 2009, 583:2009-2014.
50. Du B., Ma L.M., Huang M.B., Zhou H., Huang H.L., Shao P., Chen Y.Q., Qu L.H. High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS Lett. 2010, 584:811-816.
51. Qin W., Chung A.C., Huang X.R., Meng X.M., Hui D.S., Yu C.M., Sung J.J., Lan H.Y. TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J. Am. Soc. Nephrol. 2011, 22:1462-1474.
52. Liu Y., Taylor N.E., Lu L., Usa K., Cowley A.W., Ferreri N.R., Yeo N.C., Liang M. Renal medullary microRNAs in Dahl salt-sensitive rats: miR-29b regulates several collagens and related genes. Hypertension 2010, 55:974-982.
53. Bracken C.P., Gregory P.A., Kolesnikoff N., Bert A.G., Wang J., Shannon M.F., Goodall G.J. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008, 68:7846-7854.
54. Burk U., Schubert J., Wellner U., Schmalhofer O., Vincan E., Spaderna S., Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008, 9:582-589.
55. Zhu Y., Casado M., Vaulont S., Sharma K. Role of upstream stimulatory factors in regulation of renal transforming growth factor-beta1. Diabetes 2005, 54:1976-1984.
56. Wang S., Skorczewski J., Feng X., Mei L., Murphy-Ullrich J.E. Glucose up-regulates thrombospondin 1 gene transcription and transforming growth factor-beta activity through antagonism of cGMP-dependent protein kinase repression via upstream stimulatory factor 2. J. Biol. Chem. 2004, 279:34311-34322.
57. Weigert C., Brodbeck K., Sawadogo M., Haring H.U., Schleicher E.D. Upstream stimulatory factor (USF) proteins induce human TGF-beta1 gene activation via the glucose-response element-1013/-1002 in mesangial cells: up-regulation of USF activity by the hexosamine biosynthetic pathway. J. Biol. Chem. 2004, 279:15908-15915.
58. Oba S., Kumano S., Suzuki E., Nishimatsu H., Takahashi M., Takamori H., Kasuya M., Ogawa Y., Sato K., Kimura K., Homma Y., Hirata Y., Fujita T. miR-200b precursor can ameliorate renal tubulointerstitial fibrosis. PLoS One 2010, 5:e13614.
59. Wang B., Koh P., Winbanks C., Coughlan M.T., McClelland A., Watson A., Jandeleit-Dahm K., Burns W.C., Thomas M.C., Cooper M.E., Kantharidis P. miR-200a prevents renal fibrogenesis through repression of TGF-beta2 expression. Diabetes 2011, 60:280-287.
60. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
61. Yi J.Y., Shin I., Arteaga C.L. Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase. J. Biol. Chem. 2005, 280:10870-10876.
62. Hyun S., Lee J.H., Jin H., Nam J., Namkoong B., Lee G., Chung J., Kim V.N. Conserved microRNA miR-8/miR-200 and its target USH/FOG2 control growth by regulating PI3K. Cell 2009, 139:1096-1108.
63. Pichiorri F., Suh S.S., Rocci A., De Luca L., Taccioli C., Santhanam R., Zhou W., Benson D.M., Hofmainster C., Alder H., Garofalo M., Di Leva G., Volinia S., Lin H.J., Perrotti D., Kuehl M., Aqeilan R.I., Palumbo A., Croce C.M. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010, 18:367-381.
64. Braun C.J., Zhang X., Savelyeva I., Wolff S., Moll U.M., Schepeler T., Orntoft T.F., Andersen C.L., Dobbelstein M. p53-responsive microRNAs 192 and 215 are capable of inducing cell cycle arrest. Cancer Res. 2008, 68:10094-10104.
65. Georges S.A., Biery M.C., Kim S.Y., Schelter J.M., Guo J., Chang A.N., Jackson A.L., Carleton M.O., Linsley P.S., Cleary M.A., Chau B.N. Coordinated regulation of cell cycle transcripts by p53-inducible microRNAs, miR-192 and miR-215. Cancer Res. 2008, 68:10105-10112.
66. Kato M.V., Sato H., Nagayoshi M., Ikawa Y. Upregulation of the elongation factor-1alpha gene by p53 in association with death of an erythroleukemic cell line. Blood 1997, 90:1373-1378.
67. Kim T., Veronese A., Pichiorri F., Lee T.J., Jeon Y.J., Volinia S., Pineau P., Marchio A., Palatini J., Suh S.S., Alder H., Liu C.G., Dejean A., Croce C.M. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J. Exp. Med. 2011, 208:875-883.
68. Chang C.J., Chao C.H., Xia W., Yang J.Y., Xiong Y., Li C.W., Yu W.H., Rehman S.K., Hsu J.L., Lee H.H., Liu M., Chen C.T., Yu D., Hung M.C. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat. Cell Biol. 2011, 13:317-323.
69. Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., Vadas M.A., Khew-Goodall Y., Goodall G.J. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 2008, 10:593-601.
70. Park S.M., Gaur A.B., Lengyel E., Peter M.E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008, 22:894-907.
71. Wang B., Herman-Edelstein M., Koh P., Burns W., Jandeleit-Dahm K., Watson A., Saleem M., Goodall G.J., Twigg S.M., Cooper M.E., Kantharidis P. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes 2010, 59:1794-1802.
72. Adorno M., Cordenonsi M., Montagner M., Dupont S., Wong C., Hann B., Solari A., Bobisse S., Rondina M.B., Guzzardo V., Parenti A.R., Rosato A., Bicciato S., Balmain A., Piccolo S. A mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009, 137:87-98.
73. Zhou L., Fu P., Huang X.R., Liu F., Lai K.N., Lan H.Y. Activation of p53 promotes renal injury in acute aristolochic acid nephropathy. J. Am. Soc. Nephrol. 2010, 21:31-41.
74. Bhatt K., Zhou L., Mi Q.S., Huang S., She J.X., Dong Z. MicroRNA-34a is induced via p53 during cisplatin nephrotoxicity and contributes to cell survival. Mol. Med. 2010, 16:409-416.
75. Wei Q., Bhatt K., He H.Z., Mi Q.S., Haase V.H., Dong Z. Targeted deletion of Dicer from proximal tubules protects against renal ischemia-reperfusion injury. J. Am. Soc. Nephrol. 2010, 21:756-761.
76. Godwin J.G., Ge X., Stephan K., Jurisch A., Tullius S.G., Iacomini J. Identification of a microRNA signature of renal ischemia reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:14339-14344.
77. Elmen J., Lindow M., Schutz S., Lawrence M., Petri A., Obad S., Lindholm M., Hedtjarn M., Hansen H.F., Berger U., Gullans S., Kearney P., Sarnow P., Straarup E.M., Kauppinen S. LNA-mediated microRNA silencing in non-human primates. Nature 2008, 452:896-899.
78. Lanford R.E., Hildebrandt-Eriksen E.S., Petri A., Persson R., Lindow M., Munk M.E., Kauppinen S., Orum H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327:198-201.
79. Putta S., Lanting L., Sun G., Lawson G., Kato M., Natarajan R. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J. Am. Soc. Nephrol. 2012, 23:458-469.